scholarly journals Acute Pancreatitis as the Initial Manifestation in 2 Cases of COVID-19 in Wuhan, China

2020 ◽  
Vol 7 (9) ◽  
Author(s):  
Kaige Wang ◽  
Jianfei Luo ◽  
Fen Tan ◽  
Jiasheng Liu ◽  
Zhong Ni ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Pancreatitis ◽  
Clinical Data ◽  
Peripheral Blood ◽  
Ventilatory Support ◽  
Pancreatic Injury ◽  
Mechanical Ventilatory Support ◽  
Initial Manifestation ◽  
Poor Outcome

Abstract Clinical data on coronavirus disease 2019 (COVID-19) with pancreatic injury are extremely limited. An acute manifestation of acute pancreatitis in COVID-19 has not been reported. We describe here 2 cases of COVID-19 with acute pancreatitis as the initial manifestation in Wuhan, China. Patient 1 died despite maximal mechanical ventilatory support and circulation support, while patient 2 was finally discharged after showing significant improvement. Low T cells in peripheral blood may indicate a poor outcome.

Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 186-186
Author(s):  
Gerald Steven Falchook ◽  
Jordi Rodon Ahnert ◽  
Shree Venkat ◽  
Arthur Donahue ◽  
Peder Horner ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Clinical Data ◽  
Peripheral Blood ◽  
Immune Modulation ◽  
Mononuclear Cells ◽  
Phase 1 ◽  
Metastatic Tumor ◽  
Immune Activity ◽  
Multiple Tumor

186 Background: Toca 511 (vocimagene amiretrorepvec) is a cancer-selective, retroviral replicating vector encoding yeast cytosine deaminase that converts 5-fluorocytosine (5-FC) into 5-fluorouracil in the tumor microenvironment (TME). In animal models, Toca 511 and 5-FC kill dividing cancer and nearby immunosuppressive cells, leading to antitumor immune activity. A Phase 1 study of Toca 511 & Toca FC (extended-release 5-FC) in patients with recurrent high grade glioma revealed results consistent with this proposed mechanism. A Phase 3 trial is ongoing. Methods: Toca 6 (NCT02576665) is a Phase 1b, single-arm, multicenter study designed to investigate immunological changes after Toca 511 & Toca FC treatment in patients with advanced solid tumors, including colorectal cancer (CRC). Patients received intravenous (IV) Toca 511 for 3 days, and underwent biopsy of metastatic tumor before and ~ 4 weeks after starting oral Toca FC. Toca FC was repeated every 4-6 weeks. Peripheral blood mononuclear cells and tumor biopsies were evaluated for treatment related immune responses. Results: 17 CRC patients with a median 5 lines of prior chemotherapy were enrolled. At last data cut-off, 9 patients were alive and the median overall survival was 9.4 months. A patient receiving concomitant panitumumab had a partial response. IV Toca 511 led to viral expression in tumor, which decreased post-Toca FC while maintaining a reservoir of virus in the remaining tumor. T cells shifted from naïve to effector phenotypes, CD4 memory T cells expanded, and/or B cells increased after Toca FC treatment in 36% of patients. Marked changes in tumor infiltrating cells (CD11b myeloid cells, Tregs, exhausted T cells and CD8 T cells) occurred after Toca FC treatment. Treatment has been generally well tolerated. We also plan to report insights gained from RNA analysis of TME and update on clinical finding. Conclusions: Clinical data suggest a signal of activity in these heavily pretreated CRC patients warranting further exploration. IV Toca 511 administration showed viral infection of CRC metastatic tumor. Toca 511 & Toca FC may be associated with T cell mediated immune activity in peripheral blood and metastatic tumor, consistent with pre-clinical data in multiple tumor types. Clinical trial information: NCT02576665.

Increased frequencies of activated effector CD4+ T cells in the peripheral blood and hepatic tissue of patients with NAFL and NASH

2014 ◽  
Vol 52 (08) ◽  
Author(s):  
M Rau ◽  
AK Schilling ◽  
J Meertens ◽  
I Hering ◽  
T Kudlich ◽  
...  
Keyword(s):  
T Cells ◽  
Peripheral Blood ◽  
Cd4 T Cells ◽  
Hepatic Tissue
Sign in / Sign up

Export Citation Format

Share Document